Mel, Being bounced around from Gleevec to a Tasigna trial and then to Sprycel, and having Trisomy 8 is not the way you would like to have things go, so the distress is understandable. From your previous postings the good news has been your low blast count, which means you had not advanced to the accelerated stage. So there is reason to be grateful that you still seem to be in chronic phase.
Also, from your previous postings your PCRs seem to show that you have done the best on Tasigna, except for the low platelet issue. If it were me, I would give Tasigna another try. Sometimes the platelet issue just takes some time to resolve itself, so you might be able to tolerate it better if you give it another chance. Tasigna dosage reductions and platelet infusions could also be options until your body gets used to it. You might also want to have a Secondary Resistance BCR-ABL Mutation test done to see if you have a resistance to CML drugs (note that this is a different test than the one that found your Trisomy 8 mutation). This is a relatively new test. This test can be done by Genzyme and MolecularMD. http://www.molecularmd.com/clinTestsBCRABLMutat.php It seems that you still have drug options available since you have responded reasonably well to Tasigna. Your BMB in a couple weeks will also provide more information, so I would ask your Onc about switching back to Tasigna now that it is available, having a Secondary Resistance BCR-ABL Mutation test done, and otherwise just hang in there to see if the BMB provides any other useful information. --~--~---------~--~----~------------~-------~--~----~ [CMLHope] A support group of http://cmlhope.com ------------------------------------------------- You received this message because you are subscribed to the Google Groups "CMLHope" group. To post to this group, send email to [email protected] To unsubscribe from this group, send email to [EMAIL PROTECTED] For more options, visit this group at http://groups.google.com/group/CMLHope -~----------~----~----~----~------~----~------~--~---
